|
1
|
Morton LM, Wang SS, Devesa SS, et al:
Lymphoma incidence patterns by WHO subtype in the United States,
1992–2001. Blood. 107:265–276. 2006. View Article : Google Scholar
|
|
2
|
Coiffier B, Lepage E, Briere J, et al:
CHOP chemotherapy plus rituximab compared with CHOP alone in
elderly patients with diffuse large-B-cell lymphoma. N Engl J Med.
346:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pfreundschuh M, Trümper L, Osterborg A, et
al: CHOP-like chemotherapy plus rituximab versus CHOP-like
chemotherapy alone in young patients with good-prognosis diffuse
large-B-cell lymphoma: a randomised controlled trial by the
MabThera International Trial (MInT) Group. Lancet Oncol. 7:379–391.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ziepert M, Hasenclever D, Kuhnt E, et al:
Standard International prognostic index remains a valid predictor
of outcome for patients with aggressive CD20+ B-cell
lymphoma in the rituximab era. J Clin Oncol. 28:2373–2380. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gisselbrecht C, Glass B, Mounier N, et al:
Salvage regimens with autologous transplantation for relapsed large
B-cell lymphoma in the rituximab era. J Clin Oncol. 28:4184–4190.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
No authors listed. A predictive model for
aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s
Lymphoma Prognostic Factors Project N Engl J Med. 329:987–994.
1993.
|
|
7
|
Sehn LH, Berry B, Chhanabhai M, et al: The
revised International Prognostic index (R-IPI) is a better
predictor of outcome than standard IPI for patients with diffuse
large B-cell lymphoma treated with R-CHOP. Blood. 109:1857–1861.
2007. View Article : Google Scholar
|
|
8
|
Bari A, Marcheselli L, Sacchi S, et al:
Prognostic models for diffuse large B-cell lymphoma in the
rituximab era: a never-ending story. Ann Oncol. 21:1486–1491. 2010.
View Article : Google Scholar
|
|
9
|
Sehn LH: Paramount prognostic factors that
guide therapeutic strategies in diffuse large B-cell lymphoma.
Hematology Am Soc Hematol Educ Program. 2012:402–409.
2012.PubMed/NCBI
|
|
10
|
Perry AM, Mitrovic Z and Chan WC:
Biological prognostic markers in diffuse large B-cell lymphoma.
Cancer Control. 19:214–226. 2012.PubMed/NCBI
|
|
11
|
Alizadeh AA, Eisen MB, Davis RE, et al:
Distinct types of diffuse large B-cell lymphoma identified by gene
expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barrans S, Crouch S, Smith A, et al:
Rearrangement of MYC is associated with poor prognosis in patients
with diffuse large B-cell lymphoma treated in the era of rituximab.
J Clin Oncol. 28:3360–3365. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iqbal J, Meyer PN, Smith LM, et al: BCL2
predicts survival in germinal center B-cell-like diffuse large
B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin
Cancer Res. 17:7785–7795. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim DH, Baek JH, Chae YS, et al: Absolute
lymphocyte counts predicts response to chemotherapy and survival in
diffuse large B-cell lymphoma. Leukemia. 21:2227–2230. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Porrata LF, Ristow K, Habermann TM, et al:
Absolute lymphocyte count at the time of first relapse predicts
survival in patients with diffuse large B-cell lymphoma. Am J
Hematol. 84:93–97. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Porrata LF, Ristow K, Inwards DJ, et al:
Lymphopenia assessed during routine follow-up after
immunochemotherapy (R-CHOP) is a risk factor for predicting relapse
in patients with diffuse large B-cell lymphoma. Leukemia.
24:1343–1349. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song MK, Chung JS, Seol YM, et al:
Influence of low absolute lymphocyte count of patients with
nongerminal center type diffuse large B-cell lymphoma with R-CHOP
therapy. Ann Oncol. 21:140–144. 2010. View Article : Google Scholar
|
|
18
|
Feng J, Wang Z, Guo X, et al: Prognostic
significance of absolute lymphocyte count at diagnosis of diffuse
large B-cell lymphoma: a meta-analysis. Int J Hematol. 95:143–148.
2012. View Article : Google Scholar
|
|
19
|
Wilcox RA, Ristow K, Habermann TM, et al:
The absolute monocyte count is associated with overall survival in
patients newly diagnosed with follicular lymphoma. Leuk Lymphoma.
53:575–580. 2012. View Article : Google Scholar
|
|
20
|
Tadmor T, Bari A, Sacchi S, et al:
Monocyte count at diagnosis is a prognostic parameter in diffuse
large B-cell lymphoma: results from a large multicenter study
involving 1191 patients in the pre- and post-rituximab era.
Haematologica. 99:125–130. 2014. View Article : Google Scholar :
|
|
21
|
Wilcox RA, Ristow K, Habermann TM, et al:
The absolute monocyte and lymphocyte prognostic score predicts
survival and identifies high-risk patients in diffuse large-B-cell
lymphoma. Leukemia. 25:1502–1509. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li ZM, Huang JJ, Xia Y, et al: Blood
lymphocyte-to-monocyte ratio identifies high-risk patients in
diffuse large B-cell lymphoma treated with R-CHOP. PLoS One.
7:e416582012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rambaldi A, Boschini C, Gritti G, et al:
The lymphocyte to monocyte ratio improves the IPI-risk definition
of diffuse large B-cell lymphoma when rituximab is added to
chemotherapy. Am J Hematol. 88:1062–1067. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Watanabe R, Tomita N, Itabashi M, et al:
Peripheral blood absolute lymphocyte/monocyte ratio as a useful
prognostic factor in diffuse large B-cell lymphoma in the rituximab
era. Eur J Haematol. 92:204–210. 2014. View Article : Google Scholar
|
|
25
|
Chen LP, Lin SJ and Yu MS: Prognostic
value of platelet count in diffuse large B-cell lymphoma. Clin
Lymphoma Myeloma Leuk. 12:32–37. 2012. View Article : Google Scholar
|
|
26
|
Cheson BD, Horning SJ, Coiffier B, et al:
Report of an international workshop to standardize response
criteria for non-Hodgkin’s lymphomas. NCI Sponsored International
Working Group. J Clin Oncol. 17:12441999.
|
|
27
|
Fisher RI, Gaynor ER, Dahlberg S, et al:
Comparison of a standard regimen (CHOP) with three intensive
chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J
Med. 328:1002–1006. 1993. View Article : Google Scholar : PubMed/NCBI
|
